GlassScriptPhysician profile
Pooja Singal
NPI 1306875588
$4,993.06
in general payments reported to CMS, 2019-2025
38 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $461 · 2021: $1,563 · 2022: $1,099 · 2023: $1,108 · 2024: $248 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $715.43 | 2020-2025 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $618.29 | 2020-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $469.50 | 2020-2025 | |
| Novo Nordisk INC | $434.79 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $425.75 | 2019-2024 | Freestyle Libre 3 |
| Dexcom, INC. | $262.04 | 2021-2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $175.95 | 2020-2025 | Synthroid |
| Esperion Therapeutics, INC. | $161.82 | 2020-2024 | Nexletol |
| Horizon Therapeutics Plc | $141.74 | 2021-2023 | Tepezza |
| Insulet Corporation | $140.37 | 2021-2024 | Omnipod |
| Xeris Pharmaceuticals, INC. | $131.24 | 2020-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $129.26 | 2020-2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.64 | 2020-2023 | Jardiance |
| Antares Pharma, INC. | $112.00 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Alexion Pharmaceuticals, INC. | $110.17 | 2021-2023 | Strensiq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Singal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.